SCHEMBL5149576

SCHEMBL5149576

CCOC(=O)CCN1C(=O)CSC1c1cccc(OC(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
ACHE P22303 2/20 0.43
CACNA1B Q00975 1/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
KCNA5 P22460 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149596 0.87 CACNA1B (0.46) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5154974 0.86 HCRTR1 (0.50) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5149527 0.84 HCRTR1 (0.47) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5156906 0.84 CACNA1B (0.48) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5152374 0.82 ACHE (0.49) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5156221 0.82 POLB (0.61) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5152302 0.82 HCRTR1 (0.51) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5152211 0.82 ACHE (0.50) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL6448837 0.82 HCRTR1 (0.46) HCRTR1HCRTR2ACHECACNA1BPTGS1
SCHEMBL5153063 0.82 ACHE (0.46) HCRTR1HCRTR2ACHECACNA1BPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 HCRTR1 1608/4885HCRTR2 194/4885ACHE 3357/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I HCRTR1 2195/4885HCRTR2 251/4885ACHE 3322/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I HCRTR1 2195/4885HCRTR2 251/4885ACHE 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.